首页|不同剂量阿托伐他汀治疗冠状动脉粥样硬化性心脏病慢性心力衰竭疗效分析

不同剂量阿托伐他汀治疗冠状动脉粥样硬化性心脏病慢性心力衰竭疗效分析

扫码查看
目的 研究不同剂量阿托伐他汀治疗冠状动脉粥样硬化性心脏病(冠心病)慢性心力衰竭疗效分析.方法 选取安康市中心医院于2013年4月~2016年4月收治的100例冠心病慢性心力衰竭患者作为研究对象,随机分为2组,实验组和对照组各50例患者.2组患者均进行常规治疗,对照组患者每天给予20 mg的阿托伐他汀,实验组患者每天给予40 mg的阿托伐他汀.比较2组患者的治疗效果.结果 经过治疗后,对照组患者的左室舒张末内径显著大于实验组,左室射血分数显著低于实验组,差异均具有统计学意义(P<0.05).对照组患者出现心源性死亡以及心力衰竭复发住院的概率显著高于实验组患者,差异具有统计学意义(P<0.05).治疗前,实验组与对照组患者的血清NT-proBNP、hs-CRP水平及6MWT并无显著差异,能够进行比较.治疗后,对照组患者的血清NT-proBNP、hs-CRP水平显著高于实验组患者,6MWT显著短于实验组患者,差异具有统计学意义(P<0.05).结论 与20 mg/d阿托伐他汀相比,40 mg/d剂量阿托伐他汀治疗冠心病慢性心力衰竭疗效较好,复发率较低,安全性较高,值得临床上进一步的推广.
Effect of different doses of atorvastatin on chronic heart failure in patients with coronary heart disease
Objective To study the effect of different doses of atorvastatin in the treatment of coronary heart disease with chronic heart failure. Methods 100 patients with chronic heart failure who were admitted to Ankang Hospital from April 2013 to April 2016 were selected and randomly divided into the experimental group and the control group with a total of 50 patients in each group. Two groups of patients were treated with conventional treatment, the control group was given 20 mg of calcium a day, the experimental group was given a daily dose of 40 mg of calcium. The therapeutic effects of the two groups were compared. Results After treatment, the left ventricular end diastolic diameter in the control group was significantly higher than that in the experimental group, the left ventricular ejection fraction and E/A were significantly lower than those in the experimental group, and the difference was statistically significant (P<0.05). Patients in the control group were significantly higher than those in the experimental group in the incidence of cardiac death and recurrence of heart failure (P<0.05). Before treatment, there was no significant difference between the experimental group and the control group in serum NT-proBNP, hs-CRP levels and 6MWT. After treatment, the serum levels of NT-proBNP, hs-CRP in the control group were significantly higher than those in the experimental group, 6MWT was significantly shorter than that in the experimental group, and the difference was statistically significant (proBNP) (P<0.05). Conclusion Compared with 20mg/d, 40mg/d dose atorvastatin in the treatment of coronary heart disease with chronic heart failure curative effect, low recurrence rate, high safety, worthy of further promotion in clinical.

Ato Vatatinheart failurecoronary heart diseaseclinical efficacy

陈进业、杨甲平、王东

展开 >

安康市中心医院江北院区 心血管内科,陕西 安康 725000

安康市汉滨区第二医院 心血管内科,陕西 安康725000

安康市中心医院 心血管内科,陕西 安康 725000

阿托伐他汀 心力衰竭 冠心病 临床疗效

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(8)
  • 11
  • 9